Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study

This publication has 18 references indexed in Scilit:

• Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer?: Pro:
  European Journal Of Cancer, 1998
• Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
  Journal of Clinical Oncology, 1997
• Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial
  Annals of Oncology, 1996
• Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
  Journal of Clinical Oncology, 1996
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
  BMJ, 1995
• Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice
  European Journal Of Cancer, 1994
• Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
  Journal of Clinical Oncology, 1994
• Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial
  Annals of Oncology, 1994
• WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
  Journal of Clinical Oncology, 1987
• Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide
  British Journal of Cancer, 1980